Cerebrospinal Fluid Levels of Amyloid Beta 1-43 in Patients with Amnestic Mild Cognitive Impairment...
Cerebrospinal Fluid Levels of Amyloid Beta 1-43 in Patients with Amnestic Mild Cognitive Impairment or Early Alzheimer's Disease: A 2-Year Follow-Up Study
About this item
Full title
Author / Creator
Publisher
Switzerland: Frontiers Research Foundation
Journal title
Language
English
Formats
Publication information
Publisher
Switzerland: Frontiers Research Foundation
Subjects
More information
Scope and Contents
Contents
Biomarkers that will reliably predict the onset of Alzheimer's disease (AD) are urgently needed. Although cerebrospinal fluid (CSF) amyloid beta 1-42 (Aβ42), total tau, and phosphorylated tau can be used to complement the clinical diagnosis of AD, amnestic mild cognitive impairment (aMCI), the prodromal phase of AD, is heterogeneous. Biomarkers sho...
Alternative Titles
Full title
Cerebrospinal Fluid Levels of Amyloid Beta 1-43 in Patients with Amnestic Mild Cognitive Impairment or Early Alzheimer's Disease: A 2-Year Follow-Up Study
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_7065069f7d714c1dbe8e5170ffca6dca
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_7065069f7d714c1dbe8e5170ffca6dca
Other Identifiers
ISSN
1663-4365
E-ISSN
1663-4365
DOI
10.3389/fnagi.2016.00030
